|
Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996 EISSN: 1596-9827
Vol. 8, Num. 6, 2009, pp. 501-508
|
Tropical Journal of Pharmaceutical Research, Vol. 8, No. 6, December, 2009,
pp. 501-508
Research Article
Development of an in vitro Endotoxin Test for Monoolein–Water
Liquid Crystalline Gel for Use as an Implant
Moustapha Ouédraogo1*,
Rasmané Semdé1,
Issa T Somé1, Moussa Ouédraogo1, Rasmata Ouédraogo1,
Viviane Henschel2, Brigitte Evrard3, Jacques Dubois2,
Karim Amighi2 and Innocent P Guissou1
1UFR
- Sciences de la Santé, Université de Ouagadougou, 03 BP 7021 Ouagadougou 03,
Burkina Faso, 2Pharmacy Institute, Université Libre de Bruxelles,
Campus Plaine, Boulevard du Triomphe, B 1050 Bruxelles, 3Pharmacy
Institute, Université de Liège, CHU Tour 4, Av. de l’Hôpital, B 4000 Liège
1,
Belgium.
*Corresponding author: E-mail: moustapha_ouedraogo@univ-ouaga.bf
Received: 27 March 2009
Revised
accepted: 20 September 2009
Code Number: pr09064
Abstract
Purpose: Drugs that are administered by parenteral route must be
apyrogenic. The aim of this study was to develop an in vitro endotoxin test for
liquid crystalline gels for use as implants, using a monoolein–water liquid
crystalline gel as a model.
Methods: The gel-clot technique was used. The gel was dissolved
first in isopropyl myristate, and the endotoxins were extracted with water for
bacterial endotoxin test. Tests for the labelled lysate sensitivity and
interfering factors were performed to validate the developed method. The limit
of detection of endotoxin in the gel was also determined.
Results: The labelled lysate sensitivity was confirmed. It was
not influenced by the presence of extracts from the gels. Endotoxins in the
contaminated test gels were completely extracted. Endotoxin concentration in
the tested gels was below the calculated threshold endotoxin level.
Conclusion: A method to perform in vitro endotoxins test of liquid
crystalline gels was successfully developed and validated. Application of the
technique to gels currently being developed in our laboratories indicate that
the gels were apyrogenic.
Keywords: In
vitro bacterial endotoxin test; liquid crystalline gels; test
validation; monoolein–water.
INTRODUCTION
Drugs that are administered by the parenteral route
must be apyrogen [1-3]. Consequently, it is necessary to detect and/or quantify
endotoxins in parenteral products such as implants. Bacterial endotoxins can
provoke in humans, fever, shock, or even death [4]. To verify if parenteral
drugs are apyrogenic, tests performed in rabbits are broadly accepted.
Nevertheless, both ethical and economic reasons have led researchers to develop
alternative methods. Among these alternative techniques, the most used is the Limulus
amoebocyte lysate (LAL) test [5]. It is also known as bacterial endotoxin
test. LAL test can detect or quantify bacterial endotoxins [6].
There are three types of bacterial
endotoxin tests: gel-clot technique, which is based on gelation; turbidimetric
technique, based on the development of turbidity after cleavage of an
endogenous substrate; and chromogenic technique, based on the development of
colour after cleavage of a synthetic peptide-chromogen [7]. The first type
has this advantage: the decision to pass or fail the product under examination
is
based on the presence or absence of a gel-clot that is visible to the naked
eye. For bacterial endotoxin tests, pharmacopoeias [3,7,8] stipulate that the
test product must be soluble in or dilutable with water and it is the solution
of the test product that is mixed with the LAL reagent. However, some products
such as monoolein–water liquid crystalline gels are not soluble in water, and
worse, they solidify in contact with water [9,10]. To the best of our
knowledge, no pharmacopoeia or other literature has stipulated any protocol
for in vitro endotoxin test (LAL test) for water-insoluble gel
products.
Since our research group is currently
developing monoolein–water liquid crystalline gels of gentamycin for use
as bioresorbable implants for the treatment of chronic osteomyelitis [10-12],
we set out to develop an in vitro test method for endotoxin in this
particular product.
EXPERIMENTAL
Test product
The test product was a monoolein-water gel
containing gentamicin (5 %w/w). It was prepared in our laboratory as follows: 10 g of
gentamycin sulfate (Id Indis, Aartselar, Belgium) and 160 g of monoolein
(Danisco Pharma, Brabrand, Denmark) were separately dissolved in 50 mL of
deionized water and 50 mL of ethyl alcohol/ethyl ether 97.1/2.9 (Stella, Liège,
Belgium), respectively. The solutions were sterilised by filtration and placed
together in a 500 ml sterile glass flask that was then mounted on a rotary
evaporator (model R-205, Büchi, Switzerland). The solvent mixture was
evaporated at 50 oC, at rotating speeds varying from 150 to
235 revolutions per minute (rpm) and pressures ranging from –0.70 to –0.92 bar.
The final product was a liquid crystalline gel, which became very viscous in contact with aqueous fluids. The gel was used as a
sterile sustained-release implant [10].
Apparatus and reagents
The in vitro endotoxins test (LAL
test) was performed on samples of three batches of the gels (implants). The
following apparatus and reagents were used: heat-stable apparatus (Thermolyne,
USA); sterile and apyrogen pipettes; sterile and apyrogen tubes; vial
containing 100 IU of standard endotoxins; Limulus amoebocyte lysate
(LAL) reagent (Charles River Laboratories, USA) whose labelled lysate
sensitivity (l) was 0.015 IU/ml; apyrogen isopropyle
myristate; and water for bacterial endotoxin test (Charles River Laboratories,
USA). Solutions of standard endotoxins and Limulus amoebocyte lysate
were rehydrated with water for bacterial endotoxin test (Charles River
Laboratories, USA).
Test for confirmation of labelled lysate
sensitivity
The labelled sensitivity of the
LAL reagent was verified according to three pharmacopoeias [3,7,8] whose
methods are slightly different. In the procedures, series of two-fold dilutions
of the standard endotoxins were prepared to give concentrations of 2l, 1l, 0.5l and 0.25l where l is the labelled sensitivity of the LAL reagent in
endotoxin units per ml. Dilution of the standard endotoxins was carried out
with water for bacterial endotoxin test (BET). The test was performed at four
standard concentrations in quadruplicate and it included negative controls. A
volume (100 ml) of LAL reagent was mixed with an equal
volume of the standard solutions in each tube. The mixture was incubated in the
heat-stable apparatus at 37 ± 1 °C for 60 ± 2 min, avoiding vibration. A positive reaction was characterised by the formation of a firm gel that remained
when inverted through 180° in one smooth motion. Such a result was recorded
as positive (+). A negative result (-) was indicated by the absence of such
a gel
or by the formation of a viscous gel that did not maintain its integrity. The
test was not valid if any negative control was positive. The end-point was
the last positive result in a series of decreasing concentration of endotoxin.
The mean
value of the logarithm of the end-point concentration was calculated and then
the antilogarithm of the mean value using Eq 1.
Geometric mean end-point =
antilog [(∑e)/f] … (1)
where ∑e = sum of the log end-point concentrations of the
dilution series used and f = number of replicates.
The geometric mean
end-point concentration is the measured sensitivity of the LAL reagent (IU/ml).
If this
was not less than 0.5l and not
more than 2λ, the labelled sensitivity was confirmed
and was used in the subsequent tests performed with this LAL
reagent.
Extraction of endotoxin from the test
product
As the monoolein–water liquid crystalline
gel of gentamicin was insoluble (in water) and became solid in contact
with water, we used a technique to extract endotoxin from it as follows. An
amount
(100 mg) of the gel was placed in a tube and melted at 40 °C in the heat-stage
apparatus. The molten gel was dissolved first in 6 ml of isopropyl myristate
in the tube, and then 5 ml of water for BET was added. It was mixed for
10 min using a vortex mixer and then left to settle for 20 min. The lipidic
phase (the
supernatant) was removed and the aqueous phase (extract) used as the test
solution. Test for interfering factors was performed to validate this technique
of extraction, and to verify the absence of interference of the extract
during
LAL test.
Test for interfering factors
Solutions A, B, C and
D were prepared as shown in Table 1. The extract was the aqueous solution that
stemmed from the extraction
process. The test was performed as described for confirmation of labelled
lysate sensitivity. Different concentrations of solution B were obtained
by adding standard endotoxin to the gel so as to give theoretic concentrations
of 2λ, 1λ, 0.5λ, and
0.25λ, respectively, in solution B after
extraction.
Solution A = solution stemming from endotoxins
extraction (from the gel) and being supposed free of detectable endotoxins;
Solution B = test for interference; Solution C = control for the labelled lysate
sensitivity; Solution D = negative control (water for BET).
The geometric mean end-point concentration
of solutions B and C was determined using the expression described for
confirmation of the labelled lysate sensitivity. The test was not valid unless
all replicates of solutions A and D showed no positive reaction and the results
of solution C confirmed the labelled lysate sensitivity. If the sensitivity of
the
Table 1: Composition of solutions to be added to
LAL reagent at equal volume (100 ml)for the test for interfering factors
Solution
|
Endotoxins concentration in solution to which
endotoxins were added
|
Dilution factor
|
Endotoxins concentration
|
Number of replicates
|
A
|
None/Extract
|
|
|
4
|
B
|
2l/Extract
|
1
2
4
8
|
2l
1l
0.5l
0.25l
|
4
4
4
4
|
|
|
|
|
|
C
|
2l/Water
for BET
|
1
2
4
8
|
2l
1l
0.5l
0.25l
|
2
2
2
2
|
D
|
None/Water for BET
|
|
0
|
2
|
Solution A = solution stemming from endotoxins
extraction (from the gel) and being supposed free of detectable endotoxins;
Solution B = test for interference; Solution C = control for the labelled
lysate sensitivity; Solution D = negative control (water for BET).
lysate determined with solution B was not
less than 0.5λ and not greater than 2λ, the extract did not contain interfering
factors under the experimental conditions and the technique of extraction was
validated.
Determination of endotoxin limit
concentration in the extract and in the gel
The endotoxin limit concentration (ELC) in
the extract was determined according to the procedures of International
Pharmacopoeia and European Pharmacopoeia [3,8] using Eq 2.
ELC = (K x C) / M …………………………. (2)
where K = threshold pyrogenic dose
of endotoxins per kilogram of body mass in a single hour period; C
(concentration of the extract) = sample mass / volume of aqueous phase stemming
from extraction; M = maximum recommended dose of product per kilogram of
body mass in a single hour period. The endotoxin limit concentration in the gel
was calculated as in Eq 3.
ELCgel = ELCextract x
V/M ……………….. (3)
where V = volume of aqueous phase
stemming from extraction) and M = mass of the gel sample.
Determination of maximum valid dilution
Maximum valid dilution (MVD) is the maximum
allowable dilution of the extract at which the endotoxin limit can be
determined.
MVD = ECL/λ …………………………...
(4)
where λ = the labelled lysate sensitivity
Determination of the endotoxins
concentration in the gel
Determination of endotoxin concentration in
the gels was performed according to European Pharmacopoeia [8], using semi-quantitative
test. First, endotoxin concentration of the extract obtained from the gel was
determined. Endotoxin concentration in the gel was then computed as in Eq 5.
Cgel = Cextract x Vextract
/ Mgel ………….....
(5)
where Cgel = endotoxin concentration
of the gel, Cextract = endotoxin concentration of the
Table 2: Composition of solutions added to LAL
reagent at equal volume (100 ml) for the
determination of endotoxins concentration in the extract
Solution
|
Endotoxin concentration/ solution in which endotoxins
were added
|
Diluents
|
Dilution factor
|
Endotoxin concentration
|
Number of replicates
|
A1
|
None/Extract
|
Water for BET
|
1
2
4
8
|
|
2
2
2
2
|
B1
|
2λ/Extract
|
Extract
|
1
|
2λ
|
2
|
C1
|
2λ/Water
for BET
|
Water for BET
|
1
2
4
8
|
2λ
1λ
0.5λ
0.25λ
|
2
2
2
2
|
D1
|
None/Water for BET
|
|
|
|
2
|
Solution A1 = solution of endotoxin extract
(from gel) and presumed to be free of detectable endotoxins; Solution B1
= solution A containing standard endotoxin at a concentration of 2l (positive product control); Solution C1
= series of water for BET containing standard endotoxin at concentrations of 2l, 1l, 0.5l and 0.25l;
Solution D1 = water for BET (negative control)
extract, Vextract =
volume of the extract, and Mgel = weigth of the gel sample.
Solutions A1, B1, C1
and D1 were prepared as shown in Table 2 and tested according to the
procedure for the confirmation of the labelled lysate sensitivity described
above. The test was not validated unless the following three conditions were
met: both replicates of solution D1 (negative control) were
negative; both replicates of solution B1 (positive product control)
were positive; the geometric mean end-point concentration of solution C1
was in the range of 0.5l to 2l. To determine the endotoxin concentration
of solution A1, the end-point concentration for each replicate
series of dilutions was calculated by multiplying each end-point dilution
factor by 1l. The endotoxin concentration in the
extract was the geometric mean end-point concentration of the replicates (see
Eq 1).
If none of the dilutions of the extract was
positive, the endotoxins concentration was less than 1l. The gel met the requirements of the BET if its
endotoxin concentration was less than the endotoxin limit concentration.
Statistical analysis
Statistical analysis was performed using
GraphPad PRISM version 2.01 (GraphPad Software Inc., USA). Values of p <
0.05 were considered significant. Mann-Whitney test was used to compare the
endotoxin concentration of the gel and the theoretical (calculated) endotoxin
limit concentration (in the gel).
RESULTS
Confirmation of labelled lysate sensitivity
The results of the gel-clot tests to
confirm labelled lysate sensitivity are shown in Table 3. Geometric mean
end-point = antilog [(3log 0.015 + log 0.0075) / 4] = 0.0126 IU/ml.
Table 3: Results of the gel-clot tests to confirm
the labelled lysate sensitivity (n = 4)
Endotoxin
concentration
|
Tube number
|
1
|
2
|
3
|
4
|
2λ (= 0,030 IU/ml)
|
+
|
+
|
+
|
+
|
1λ (= 0,015 IU/ml)
|
+
|
+
|
+
|
+
|
0.5λ (= 0,0075 IU/ml)
|
-
|
-
|
+
|
-
|
0.25λ (= 0,0037 IU/ml)
|
-
|
-
|
-
|
-
|
0λ (= water for BET)
|
-
|
-
|
-
|
-
|
- = absence of
formation of viscous gel (negative reaction)
+ = formation of
viscous gel (positive reaction)
Table 4: The results of gel-clot tests to verify absence of
interfering factors during BET of the gels (n = 4)
Solution
|
Endotoxin concentration/ solution in which endotoxins
were added
|
Initial endotoxin concentration
|
Tube number
|
1
|
2
|
3
|
4
|
A
|
None/Extract
|
|
-
|
-
|
-
|
-
|
B
|
2λl/Extract
|
2λ (=
0,030 IU/ml)
1λ (=
0,015 IU/ml)
0.5λ (=
0,0075 IU/ml)
0.25l (= 0,0037 IU/ml)
|
+
+
-
-
|
+
+
-
-
|
+
+
-
-
|
+
+
-
-
|
C
|
2λ/Water for BET
|
2λ
1λ
0.5λ
0.25λ
|
+
+
-
-
|
+
+
-
-
|
+
+
-
-
|
+
+
-
-
|
D
|
None/Water for
BET
|
0
|
-
|
-
|
-
|
-
|
- = absence of
formation of viscous gel (negative reaction)
+ = formation of
viscous gel (positive reaction)
Therefore, the measured sensitivity of the
LAL reagent was 0.0126 IU/ml.
Test for interfering factors
Table 4 shows the results of the gel-clot
tests verifying absence of interfering factors during BET of the gel. The
geometric mean end-point concentration of solutions B and C (i.e., sensitivity
of the lysate with solutions B and C) was equal to antilog [(4log 0.015)/4] =
0,015 IU/ml.
Endotoxin limit concentration (ELC)
The maximum recommended dose of the gel per
kg body weight (over a 24 h period) was 1.71 g, i.e., 0.0712 g/kg/h. The lowest threshold pyrogenic dose of endotoxins per kg body weight over a single hour
period (K) was 0.2 IU. The concentration of the test solution was 100 mg/5 ml,
i.e., 20 mg/ml. ELC in the extract = (0.2 IU/kg/h x 20 mg/ml)/ 71.2 mg/kg/h,
i.e., 0.056 IU/ml. Therefore, ELC in the gel was (0.056 IU/ml x 5 ml)/ 100 mg,
i.e., 0.0028 IU/mg. Thus, the maximum valid dilution (MVD) of the extract was
(0.056 IU/ml)/ 0.015 IU/ml, i.e., 3.73.
Endotoxin concentration in the gel
Table 5 shows the results of gel-clot tests
to determine endotoxin concentration in the extract. These results were similar
for all the three batches of the gel. The geometric mean end-point
concentration of solution C1 = antilog [(2log 0.015)/2], i.e., 0.015
IU/ml. As neither diluted extract nor initial extract was positive, the
endotoxin concentration in the extract was less than l, i.e., 0.015 IU/ml. Therefore, the endotoxin
concentration in the
Table 5: The results
of gel-clot tests to determine endotoxin concentration in extracts (n = 4)
Solution
|
Endotoxin concentration/ solution in which
endotoxins were added
|
Dilution factor
|
Initial endotoxin concentration
|
Tube
|
A1
|
None/Extract
|
1
2
4
8
|
|
-
-
-
-
|
-
-
-
-
|
B1
|
2l/Extract
|
1
|
2λ
|
+
|
+
|
C1
|
2l/Water
for BET
|
1
2
4
8
|
2λ
1λ
0.5λ
0.25λ
|
+
+
-
-
|
+
+
-
-
|
D1
|
None/Water for BET
|
|
0
|
-
|
-
|
- = absence of
formation of viscous gel (negative reaction)
+ = formation of
viscous gel (positive reaction)
gel was less than (0.015 IU/ml x 5ml)/100
mg, i.e., 0.00075 IU/mg.
DISCUSSION
The gel-clot technique for bacterial endotoxins test
is based on the gelation of a lysate of amoebocytes (limulus amoebocyte
lysate) from the horseshoe crab, Limulus polyphemus or Limulus
tachypleus. The addition of a solution containing endotoxins (at least 1l concentration) to a solution of the lysate
produces gelation of the mixture; l
is the labelled lysate sensitivity.
The sensitivity of the lysate (LAL reagent)
in the presence or absence of the extract was at least 0.5 times but not more
than twice the labelled lysate sensitivity, i.e., between 0.0075 and 0.0300
IU/ml. All negative controls were negative and positive controls were positive
for all gel-clot tests (Tables 3 - 5). According to pharmacopoeias [3,7,8],
these results confirm the sensitivity of the labelled lysate. The extract
neither inhibited nor activated gel formation (see Table 4), suggesting that it
was suitable for bacterial endotoxin test. The sensitivity of the lysate
remained valid when it was determined with a solution derived from artificially
contaminated gel (see results of the test for interfering factors). Therefore,
the developed technique achieved the extraction of the whole endotoxin from the
gel.
Due to the physicochemical properties of
the gel, we could not extract endotoxin directly with water for BET [10]. It
was only feasible after dissolution of the gel in lipidic solvent (isopropyl
myristate). The hydrophilic property of the endotoxin enabled them to migrate
in the aqueous phase after liquid-liquid phase extraction. Endotoxins, which
are lipopolysaccharides, are composed of a hydrophilic polysaccharide moiety,
which is covalently linked to a hydrophobic lipid moiety [13].
As monoolein–water liquid crystalline gel
of gentamicin is a novel product, their endotoxin limit concentration is not
specified in the pharmacopoeias used [3,7,8]. However, the pharmacopoeias state
recommendations for determining this parameter. In our study, the endotoxin
limit concentration was calculated using parameters that afford the greatest
safety to patients. Consequently, the lowest threshold pyrogenic dose of
endotoxins per kg body weight over a single hour period (K) suggested by
European Pharmacopoeia was used (0.2 IU).
The endotoxin concentration in the gels
(< 0.00075 IU/mg) was less than the calculated endotoxin limit concentration
(0.0028 IU/mg) (p < 0.001). The tested gels were apyrogenic and met the
requirements of three pharmacopoeias used [3,7,8]. This assertion is justified
by the absence of bacterial endotoxin in the product which implies the absence
of pyrogenic components [8]. Though pyrogens are a chemically heterogeneous
group of fever-inducing compounds, endotoxins from Gram-negative bacteria are
of major concern to the pharmaceutical industry due to their ubiquitous
sources, stability and highly toxic reactions [6,14].
CONCLUSION
We have demonstrated that it is possible to
perform in vitro endotoxin test (BET) on liquid crystalline gels.
Application of this developed technique enabled us to perform in vitro
endotoxins test of a monoolein–water liquid crystalline gel intended for use as
an implant. The tested batches of gel were apyrogenic under the conditions of
the study. The in vitro endotoxin test
that we developed may be used to assess the safety of a wide range of insoluble
parenteral drugs.
ACKNOWLEDGMENT
The authors would like to thank Coopération
Universitaire au Développement/ Commission Interuniversitaire Francophone
(CUD/CIUF), Association pour la Promotion de la Formation et de l’Education à l’Etranger (APEFE), and Commissariat Général aux Relations
Internationales (CGRI) of Belgium for their financial support for this study.
REFERENCES
-
Avis EK,
Lieberman AH, Lachman L. Pharmaceutical dosage forms: parenteral medication.
Volume 2. 2nd ed., Marcel Dekker, Inc, New York, 1993
- Poole
S, Mistry Y, Ball C, Rose E, Gaines Das REG, Opie LP, Tucker G, Patel M.
A rapid ‘one-plate’ in vitro test for pyrogens. J Immunol Methods,
2003; 274: 209– 220.
- The
International Pharmacopoeia, World Health Organization (WHO), Geneva, 4th ed,
2006; 30-32.
- Zijlstra
S, Gerken P, Rechin C, Wortmann R, Notohamiprodjo G. Validation of the
limulus amebocyte(LAL) test for routine PET Radiopharmaceuticals Lysate.
Appl. Radiat
Isot, 1997; 48(1): 51-54.
- Eperon
S, De Groote D, Werner-Felmayer G, Jungi TW. Human monocytoid cell lines
as indicators of endotoxin: comparison with rabbit pyrogen and Limulus amoebocyte
lysate assay. J Immunol Methods, 1997; 207: 135-145.
- Hoffmann
S, Peterbauere A, Schindler S, Fennrich S, Poole S, Mistry Y, Montag-Lessing
T, Spreitzer I, Lfschner B, Van Aalderen M et al. International validation
of novel
pyrogen tests based on human monocytoid cells. J Immunol Methods, 2005 ;
298 : 161– 173.
- United
States
Pharmacopeia, 25th ed. Rockville, USA: United States Pharmacopeial
Convention, Inc, 2002; 1829-1830.
- European
Pharmacopoeia, 5th ed, Paris: Jouve, 2005; 89-96.
- Rowe
RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed.,
The pharmaceuticals society of Great Britain and the American pharmaceutical
association, Washington, London, 2003.
- Ouédraogo M, Semdé R, Somé
TI, Traoré-Ouédraogo R, Guissou IP, Henschel V, Dubois J, Amighi K, Evrard B.
Monoolein–Water Liquid Crystalline Gels of Gentamicin as Bioresorbable Implants
for the Local Treatment of Chronic Osteomyelitis: In Vitro Characterization. Drug
Dev Ind Pharm, 2008; 34: 753–760.
- Ouédraogo M, Sanou M,
Ramdé N, Goumbri O, Somé TI, Semdé R, Ouédraogo R, Guissou IP, Henschel V,
Evrard B, Amighi K, Dubois J. In vivo Biocompatibility and Toxicity Assessment
of a Gentamicin-Loaded Monoolein Gel Intended to Treat Chronic Osteomyelitis.
J.
Pharmacol. Toxicol., 2008; 3(5): 386-393.
- Ouédraogo M, Nacoulma WC,
Semdé R, Somé TI, Guissou IP, Henschel V, Evrard B, Amighi K, Dubois J. In
Vitro Biocompatibility and Genotoxicity Assessment of a Gentamicin-Loaded
Monoolein Gel Intended to Treat Chronic Osteomyelitis. J. Pharmacol. Toxicol.,
2008; 3(5): 386-393.
- Magalahaes
PO, Lopes AM, Mazolla PG, Rangel-Yagui C, Penna TCV, Pessoa Jr A. Methods
of Endotoxins Removal from Biological Preparations: a Review. J Pharm Pharmaceut
Sci. 2007;
10(3): 388-404.
- ennrich S, Fischer M,
Hartung T, Lexa P, Montag-Lessing T, Sontag HG, Weigandt M, Wendel A. Detection
of endotoxins and other pyrogens using
|